Skip to main content

Bebtelovimab FDA Approval Status

FDA Approved: No
Generic name: bebtelovimab
Dosage form: Injection
Company: Eli Lilly and Company
Treatment for: COVID-19

Bebtelovimab is an investigational human immunoglobulin G-1 (IgG1 variant) monoclonal antibody (mAb) directed against the spike protein of SARS-CoV-2 for the treatment of COVID-19.

Development timeline for bebtelovimab

Nov 30, 2022FDA Announces Bebtelovimab is Not Currently Authorized in Any US Region
Feb 11, 2022Lilly's Bebtelovimab Receives Emergency Use Authorization for the Treatment of Mild-to-Moderate COVID-19

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.